Jamieson Wellness Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

 

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today reported financial results for its fourth quarter and year ended December 31, 2022. All amounts are expressed in Canadian dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS and other financial measures. See "Non-IFRS and Other Financial Measures" below.

 

  Highlights of Fourth Quarter 2022 Results versus Fourth Quarter 2021 Results  

 
  • Revenue increased by 48.5% to $192.8 million;
  •  
  • Jamieson Brands revenue increased by 56.3%, with organic growth of 5.6%;
  •  
  • Adjusted EBITDA (1) increased by 44.7% to $48.9 million;
  •  
  • Net earnings were $22.1 million and Adjusted net earnings (1) increased 30.6% to $26.8 million; and
  •  
  • Diluted earnings per share were $0.52, and Adjusted diluted earnings per share (2) increased 26.5% to $0.62
  •  

  Highlights of Full Year 2022 Results versus Full Year 2021 Results  

 
  • Revenue increased by 21.4% to $547.4 million;
  •  
  • Jamieson Brands revenue increased by 27.9%, with organic growth of 8.1%;
  •  
  • Adjusted EBITDA (1) increased by 23.6% to $123.8 million;
  •  
  • Net earnings were $52.8 million and Adjusted net earnings (1) increased 18.0% to $65.1 million; and
  •  
  • Diluted earnings per share were $1.25, and Adjusted diluted earnings per share (2) increased 17.4% to $1.55
  •  

"2022 was a transformative year for Jamieson Wellness," said Mike Pilato, President and CEO of Jamieson Wellness. "In addition to celebrating our 100th year of improving the world's health and wellness with our Jamieson brand, we made significant advancements in our primary growth pillars as we continue to expand our category leadership globally beyond this milestone year.

 

"Throughout 2022, we saw consistent growth in our brands in Canada, as Canadian consumers continued to trust Jamieson for their health and wellness needs. In July, we closed on our acquisition of the youtheory brand, providing us with a strong platform and premium brand offering in the United States. In just a few short months we have identified and begun to execute multiple opportunities to leverage our combined strengths across channels, product innovation and capabilities to drive revenues and profitability in 2023 and beyond. In November, we announced the pending acquisition of our Chinese distributor's assets. This is a natural evolution of our strategy and supports significant brand expansion as we transition to full control of the value chain, enabling us to capitalize on our strong momentum in the world's second largest VMS market.

 

"These major strategic actions defined our centennial year and have placed us in a strong position for growth as we enter our next century of helping consumers around the world optimize their health and wellness. We delivered solid performance across our business in 2022 with total revenues up 21%, while profitability was similarly strong with adjusted EBITDA increasing 24%. We are extremely proud of our team for our achievements in 2022, and equally excited for the future. In 2023, we will continue to invest in our long-term opportunities, with a focus on our four primary growth pillars of Canada, U.S., China and International. We will continue to build our world-class brands by leveraging our best-in-class marketing, innovation and omni channel distribution capabilities to drive significant global expansion of our high-quality products and enhance value for all stakeholders."

 

  Fourth Quarter 2022 versus Fourth Quarter 2021 Results  

 

Revenue increased 48.5% to $192.8 million in the fourth quarter of 2022 driven by 56.3% growth in the Jamieson Brands segment and 22.4% growth in the Strategic Partners segment.

 
  • Jamieson Brands segment revenue increased by $56.2 million or 56.3% driven by the following:
    • Jamieson Canada revenue growth of 6.3%, reflecting continued consumer demand, higher average retailer inventories in conjunction with a severe cold & flu season, and in-year pricing;
    •  
    • Jamieson China revenue growth of 41.5%, reflecting strong consumer demand as COVID-19 related lockdowns were eliminated in the quarter;
    •  
    • Jamieson International revenue decline of 21.0%, largely resulting from geopolitical and economic pressures in eastern Europe and delayed entry into certain markets due to regulatory changes;
    •  
    • Newly acquired youtheory business in 2022 contributed revenue of $50.6 million driven by seasonally higher promotions ahead of new year offset by lower customer inventory levels as specific partners reduced stocks on-hand in support of 2023 innovation plans.
    •  
  •  
  • Strategic Partners segment revenue increased by $6.7 million or 22.4%, to $36.8 million reflecting pricing to maintain existing margin structure and volume changes of customer products.
  •  

Gross profit increased 44.1% to $71.2 million in the fourth quarter of 2022. Gross profit margin (3) decreased by 120 basis points to 36.9% in the fourth quarter of 2022, driven by 80 basis points from youtheory gross profit margins which are inherently lower than the base business and 40 basis points due to a higher proportion of Strategic Partner sales.

 

Selling, general and administrative ("SG&A") expenses increased by $13.2 million to $32.8 million in the fourth quarter of 2022. Normalized SG&A (1) increased by $8.8 million driven by the inclusion of the youtheory acquisition of $7.0 million while expanding its resources and marketing activity plus $1.8 million in the base business.

 

Earnings from operations increased 28.5% to $37.1 million in the fourth quarter of 2022 and operating margin (3) decreased by 300 basis points to 19.2% due to factors affecting gross profit margin and higher SG&A investments discussed above. Normalized earnings from operations (1) increased by $13.4 million or 46.2% in the fourth quarter of 2022 and normalized operating margin (2) was 22.0% compared with 22.4% in the fourth quarter of 2021.

 

Adjusted EBITDA increased by 44.7% to $48.9 million in the fourth quarter of 2022 and Adjusted EBITDA margin (2) was 25.4% compared with 26.0% in the fourth quarter of 2021 as youtheory Adjusted EBITDA margins are inherently lower than the base business.

 

Interest expense and other financing costs increased by $4.4 million to $5.8 million due to higher average borrowing rates and higher borrowings to support the youtheory acquisition.

 

Net earnings for the fourth quarter of 2022 were $22.1 million compared with $20.2 million in the fourth quarter of 2021. Adjusted net earnings increased by $6.3 million, or 30.6%, to $26.8 million in the fourth quarter of 2022.

 

Adjusted net earnings in the quarter exclude costs associated with foreign exchange gain/loss, acquisition related costs, IT system improvements, and other non-operating earnings or expenses net of related tax effects. A quantitative reconciliation of reported net earnings to EBITDA, Adjusted EBITDA, and non-IFRS normalized gross profit, normalized SG&A, normalized earnings from operations and Adjusted net earnings are included in the table accompanying this release under the heading "Non-IFRS and Other Financial Measures".

 

  Balance Sheet & Cash Flow  

 

The Company generated $40.8 million in cash from operations during the fourth quarter of 2022 compared with $34.3 million generated in the fourth quarter of 2021. Cash from operating activities before working capital considerations (1) of $29.1 million was $4.5 million higher due to increased earnings in the current quarter. Cash generated from working capital increased by $1.9 million mainly driven by favourable timing of payables and accelerated inventory purchases realized earlier in 2022. The Company's cash as at December 31, 2022 was $26.2 million compared with $6.8 million on December 31, 2021 due to foreign currencies (U.S. dollars) held for short-term obligations in Canada as well as the impact of its expanded global operations. The Company ended the year with approximately $126.2 million in cash and available operating lines and net debt (1) of $373.8 million.

 
                                                                                                                                                                                                                               
    Three months ended      
    December 31      
  ($ in 000's, except as otherwise noted)    

  2022  

 
  

  2021  

 
  

  $ Change  

 
  

  % Change  

 
         
Cash, beginning of period   

  7,316  

 
 

 

 
  

  9,150  

 
 

 

 
  

  (1,834  

 
 

  )  

 
  

  (20.0  

 
 

  %)  

 
Cash flows from (used in):         
Operating activities   

40,799

 
 

 

 
  

34,309

 
 

 

 
  

6,490

 
 

 

 
  

18.9

 
 

%

 
Investing activities   

(2,692

 
 

)

 
  

(5,399

 
 

)

 
  

2,707

 
 

 

 
  

50.1

 
 

%

 
Financing activities   

(19,183

 
 

)

 
  

(31,285

 
 

)

 
  

12,102

 
 

 

 
  

38.7

 
 

%

 
  Cash, end of period    

  26,240  

 
 

 

 
  

  6,775  

 
 

 

 
  

  19,465  

 
 

 

 
  

  287.3  

 
 

  %  

 
         
Cash flows from operating activities   

40,799

 
 

 

 
  

34,309

 
 

 

 
  

6,490

 
 

 

 
  

18.9

 
 

%

 
Net Change in non-cash working capital   

(11,741

 
 

)

 
  

(9,799

 
 

)

 
  

(1,942

 
 

)

 
  

(19.8

 
 

%)

 
  Cash from operating activities before working capital considerations    

  29,058  

 
 

 

 
  

  24,510  

 
 

 

 
  

  4,548  

 
 

 

 
  

  18.6  

 
 

  %  

 
         
         
  ($ in 000's, except as otherwise noted)        

  As at December  

 

  31, 2022  

 
  

  As at December  

 

  31, 2021  

 
         
  Long-term debt        

  400,000  

 
 

 

 
  

  149,125  

 
 

 

 
Cash       

(26,240

 
 

)

 
  

(6,775

 
 

)

 
  Net debt        

  373,760  

 
 

 

 
  

  142,350  

 
 

 

 
 

  Fiscal 2023 Outlook  

 

The Company is introducing its outlook for fiscal 2023 and anticipates revenue in a range of $670.0 to $700.0 million, which represents annual growth of 22.0% to 28.0%. The Company estimates Adjusted EBITDA in a range of $140.0 to $146.0 million representing approximately 13.0% to 18.0% growth and Adjusted diluted earnings per share in a range of $1.62 to $1.72.

 

This outlook for revenue growth reflects the following assumptions:

 
  • Jamieson Brands segment revenue growth of 24.0% to 30.0%, driven by the following:
    • Jamieson Canada revenue growth of 3.0% to 6.0%, reflecting continued consumer demand, marketing plans, innovation, and the impact of prior year pricing;
    •  
    • Youtheory revenue of between $145.0 and $155.0 million (approximately 11.5% to 19.0% on a pro-forma basis) driven by product innovation, expanded e-commerce initiatives and distribution gains;
    •  
    • Jamieson China revenue to increase by 65.0% to 75.0%, reflecting a transition to an owned distribution model and the related step-up in distributor level pricing realized on revenues beginning the second quarter of 2023 along with continued consumer demand in e-commerce and distribution gains in the domestic retail channels (approximately 25.0% to 30.0% growth on a pro-forma basis);
    •  
    • Jamieson International revenue growth of 5.0% to 20.0% driven by marketing, innovation, and distribution into new markets as well as expansion across key regions.
    •  
  •  
  • Strategic Partners segment revenue growth of 15.0% to 20.0%, reflecting pricing to maintain existing margin structure and program changes with existing customers.
  •  

The outlook for Adjusted EBITDA growth and Adjusted diluted earnings per share reflect the following assumptions:

 
  • Gross profit margin to remain consistent with the prior year as the expected decline in Jamieson Brands margins is offset by favourable customer and program mix impacting Strategic Partners. Jamieson Brands margins will be approximately 100 basis points lower impacted by the full year inclusion of youtheory and the transition to an owned distribution model in China;
  •  
  • Normalized SG&A including marketing expenses are expected to increase 35.0% to 40.0% based on the acquisition of youtheory and an accelerated investment in marketing, resources and infrastructure to support long-term growth opportunities in the United States and in China;
  •  
  • Based on the resource and marketing investments being made to drive long term growth, adjusted EBITDA margins are expected to decline by 175 basis points in 2023. The decline includes the margin profile of the acquired businesses and proportionate revenue growth within Strategic Partners;
  •  
  • Interest expense of $17.5 to $18.5 million reflecting incremental debt to fund the acquisition and higher prevailing interest rates.
  •  

For additional details on the Company's fiscal 2023 outlook, including guidance for the first quarter of 2023, refer to the "Outlook" section in the management's discussion and analysis of financial condition and results of operations ("2022 MD&A") for the three and twelve months ended December 31, 2022.

 

  Declaration of Fourth Quarter Dividend  

 

The board of directors of the Company authorized and declared a cash dividend for the fourth quarter of 2022 of $0.17 per common share, or approximately $7.1 million in the aggregate. The dividend will be paid on March 15, 2023 to all common shareholders of record at the close of business on March 3, 2023. The Company has designated this dividend as an "eligible dividend" for the purposes of the Income Tax Act (Canada).

 

  New Partnership with DCP Capital to Support Strategic Growth Plan in China  

 

Also announced today, the Company has entered into a partnership with DCP Capital ("DCP"), a leading international private equity firm with a long-term track record of success in Greater China and broader Asian markets. DCP will purchase a minority interest in the Company's Chinese operations and make a preferred share investment in Jamieson Wellness. In conjunction with these investments, DCP will be granted warrants to purchase a fixed number of common shares of the Company. The partnership will leverage the combined expertise of both companies and is expected to accelerate Jamieson Wellness' strong organic growth in China. Details on the pending transaction can be found in a separate media release issued this afternoon.

 

  Consolidated Financial Statements and Management's Discussion and Analysis  

 

The Company's audited consolidated annual financial statements and accompanying notes as at and for the three and twelve months ended December 31, 2022 and related MD&A are available under the Company's profile on SEDAR at www.sedar.com and on the Investor Relations section of the Company's website at https://investors.jamiesonwellness.com .

 

  Conference Call  

 

Management will host a conference call to discuss the Company's fourth quarter and full year 2022 results at 5:00 p.m. ET today, February 23, 2023. The call can be accessed live over the telephone by dialing 1-888-394-8218 from Canada and the U.S. or 1-323-994-2093 from international locations. A replay will be available shortly after the call and can be accessed by dialing 1-844-512-2921 from Canada and the U.S. or 1-412-317-6671 from international locations. The passcode for the replay is 1883631 and it will be available until Thursday March 9, 2023.

 

Interested parties may listen to a simultaneous webcast of the conference call by logging on via the Investor Relations section of the Company's website at https://investors.jamiesonwellness.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1594444&tp_key=5d1e64a28e . A replay of the webcast will be available for approximately 30 days following the call.

 

  About Jamieson Wellness  

 

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness also offers a variety of VMS products under its youtheory, Progressive, Smart Solutions, Iron Vegan and Precision brands. The Company is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. For more information please visit www.jamiesonwellness.com .

 

Jamieson Wellness' head office is located at 1 Adelaide Street East Suite 2200, Toronto, Ontario, Canada.

 

  Forward-Looking Information  

 

This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company's anticipated results and its outlook for its 2023 revenue, Adjusted EBITDA and Adjusted diluted earnings per share. Words such as "expect", "anticipate", "intend", "may", "will", "estimate" and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under "Risk Factors" in the Company's Annual Information Form dated March 29, 2022 and under the "Risk Factors" section in the MD&A filed today, February 23, 2023. This information is based on the Company's reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.

 

The Company cautions that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company's results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See "Forward-looking Information" and "Risk Factors" within the MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements.

 

____________________
(1) This is a non-IFRS financial measure. See the " Non-IFRS and Other Financial Measures " section of this press release for more information on each non-IFRS financial measure.
(2) This is a non-IFRS ratio. See the " Non-IFRS and Other Financial Measures " section of this press release for more information on each non-IFRS ratio.
(3) This is a supplementary financial measure. See the " Non-IFRS and Other Financial Measures " section of this press release for more information on each supplementary financial measure.

 
                                                                                                                                                                                                                                                                                                                                                                                                                              
 

  Jamieson Wellness Inc.  

 

Selected Consolidated Financial Information

 

In thousands of Canadian dollars, except share and per share amounts

 
     
    Three months ended     Twelve months ended  
    December 31     December 31  
   

  2022  

 
 

 

 
  

  2021  

 
 

 

 
  

  2022  

 
 

 

 
  

  2021  

 
 

 

 
         
  Revenue    

  192,775  

 
 

 

 
  

  129,838  

 
 

 

 
  

  547,369  

 
 

 

 
  

  451,032  

 
 

 

 
Cost of sales   

121,586

 
 

 

 
  

80,422

 
 

 

 
  

349,031

 
 

 

 
  

288,591

 
 

 

 
Gross profit   

71,189

 
 

 

 
  

49,416

 
 

 

 
  

198,338

 
 

 

 
  

162,441

 
 

 

 
         
  Gross profit margin    

  36.9  

 
 

  %  

 
  

  38.1  

 
 

  %  

 
  

  36.2  

 
 

  %  

 
  

  36.0  

 
 

  %  

 
         
Selling, general and administrative expenses   

32,768

 
 

 

 
  

19,521

 
 

 

 
  

110,239

 
 

 

 
  

80,739

 
 

 

 
Share-based compensation   

1,317

 
 

 

 
  

1,021

 
 

 

 
  

4,910

 
 

 

 
  

5,672

 
 

 

 
  Earnings from operations    

  37,104  

 
 

 

 
  

  28,874  

 
 

 

 
  

  83,189  

 
 

 

 
  

  76,030  

 
 

 

 
         
  Operating margin    

  19.2  

 
 

  %  

 
  

  22.2  

 
 

  %  

 
  

  15.2  

 
 

  %  

 
  

  16.9  

 
 

  %  

 
         
Foreign exchange loss/(gain)   

978

 
 

 

 
  

352

 
 

 

 
  

269

 
 

 

 
  

(92

 
 

)

 
Interest expense and other financing costs   

5,757

 
 

 

 
  

1,366

 
 

 

 
  

12,417

 
 

 

 
  

5,657

 
 

 

 
Earnings before income taxes   

30,369

 
 

 

 
  

27,156

 
 

 

 
  

70,503

 
 

 

 
  

70,465

 
 

 

 
Provision for income taxes   

8,278

 
 

 

 
  

6,966

 
 

 

 
  

17,695

 
 

 

 
  

18,383

 
 

 

 
  Net earnings    

  22,091  

 
 

 

 
  

  20,190  

 
 

 

 
  

  52,808  

 
 

 

 
  

  52,082  

 
 

 

 
  Adjusted net earnings    

  26,759  

 
 

 

 
  

  20,489  

 
 

 

 
  

  65,149  

 
 

 

 
  

  55,217  

 
 

 

 
         
  EBITDA    

  41,201  

 
 

 

 
  

  32,225  

 
 

 

 
  

  100,168  

 
 

 

 
  

  90,396  

 
 

 

 
  Adjusted EBITDA    

  48,871  

 
 

 

 
  

  33,771  

 
 

 

 
  

  123,761  

 
 

 

 
  

  100,096  

 
 

 

 
         
  Adjusted EBITDA margin    

  25.4  

 
 

  %  

 
  

  26.0  

 
 

  %  

 
  

  22.6  

 
 

  %  

 
  

  22.2  

 
 

  %  

 
         
  Weighted average number of shares          
Basic   

41,683,753

 
 

 

 
  

40,371,018

 
 

 

 
  

40,998,065

 
 

 

 
  

40,150,724

 
 

 

 
Diluted   

42,817,044

 
 

 

 
  

41,921,765

 
 

 

 
  

42,116,350

 
 

 

 
  

41,680,934

 
 

 

 
         
  Earnings per share attributable to common shareholders:          
Basic, earnings per share   

  0.53  

 
 

 

 
  

  0.50  

 
 

 

 
  

  1.29  

 
 

 

 
  

  1.30  

 
 

 

 
Diluted, earnings per share   

  0.52  

 
 

 

 
  

  0.48  

 
 

 

 
  

  1.25  

 
 

 

 
  

  1.25  

 
 

 

 
Adjusted diluted, earnings per share   

  0.62  

 
 

 

 
  

  0.49  

 
 

 

 
  

  1.55  

 
 

 

 
  

  1.32  

 
 

 

 
 
                                                                                                                                                                                               
 

  Jamieson Wellness Inc.  

 

Consolidated Statements of Financial Position

 

In thousands of Canadian dollars

 
     
   

  December 31,  

 

  2022  

 
 

 

 
 

  December 31,  

 

  2021  

 
  Assets      
  Current assets      
Cash   

26,240

 
  

6,775

 
Accounts receivable   

160,798

 
  

104,186

 
Inventories   

154,488

 
  

119,006

 
Derivatives   

6,580

 
  

2,149

 
Prepaid expenses and other current assets   

4,298

 
  

5,029

 
   

  352,404  

 
  

  237,145  

 
  Non-current assets      
Property, plant and equipment   

111,709

 
  

96,977

 
Goodwill   

272,916

 
  

122,975

 
Intangible assets   

367,205

 
  

192,676

 
Deferred income tax   

3,029

 
  

2,702

 
  Total assets    

  1,107,263  

 
  

  652,475  

 
     
  Liabilities      
  Current liabilities      
Accounts payable and accrued liabilities   

142,566

 
  

74,533

 
Income taxes payable   

7,387

 
  

2,896

 
Derivatives   

-

 
  

3,317

 
Current portion of other long-term liabilities   

4,852

 
  

2,876

 
   

  154,805  

 
  

  83,622  

 
  Long-term liabilities      
Long-term debt   

400,000

 
  

149,125

 
Post-retirement benefits   

929

 
  

3,544

 
Deferred income tax   

58,007

 
  

53,291

 
Other long-term liabilities   

61,931

 
  

20,872

 
  Total liabilities    

  675,672  

 
  

  310,454  

 
     
  Shareholders' equity      
Share capital   

307,200

 
  

268,214

 
Contributed surplus   

17,115

 
  

14,786

 
Retained earnings   

85,483

 
  

58,998

 
Accumulated other comprehensive income   

21,793

 
  

23

 
  Total shareholders' equity    

  431,591  

 
  

  342,021  

 
  Total liabilities and shareholders' equity    

  1,107,263  

 
  

  652,475  

 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
 

  Jamieson Wellness Inc.  

 

Segment Information

 

In thousands of Canadian dollars, except as otherwise noted

 
       
 

  Jamieson Brands  

 
      
   

  Three months ended  

 

  December 31  

 
    
   

  2022  

 
 

 

 
  

  2021  

 
 

 

 
  

  $ Change  

 
  

  % Change  

 
         
Revenue   

155,996

 
 

 

 
  

99,784

 
 

 

 
  

56,212

 
 

 

 
  

56.3

 
 

%

 
         
Gross profit   

65,345

 
 

 

 
  

45,157

 
 

 

 
  

20,188

 
 

 

 
  

44.7

 
 

%

 
Gross profit margin   

41.9

 
 

%

 
  

45.3

 
 

%

 
  

-

 
 

 

 
  

(3.4

 
 

%)

 
         
Normalized gross profit   

66,138

 
 

 

 
  

45,157

 
 

 

 
  

20,981

 
 

 

 
  

46.5

 
 

%

 
Normalized gross profit margin   

42.4

 
 

%

 
  

45.3

 
 

%

 
  

-

 
 

 

 
  

(2.9

 
 

%)

 
         
Selling, general and administrative expenses   

31,165

 
 

 

 
  

17,905

 
 

 

 
  

13,260

 
 

 

 
  

74.1

 
 

%

 
Normalized selling, general and administrative expenses   

26,583

 
 

 

 
  

17,781

 
 

 

 
  

8,802

 
 

 

 
  

49.5

 
 

%

 
         
Share-based compensation   

1,317

 
 

 

 
  

1,021

 
 

 

 
  

296

 
 

 

 
  

29.0

 
 

%

 
         
  Earnings from operations    

  32,863  

 
 

 

 
  

  26,231  

 
 

 

 
  

  6,632  

 
 

 

 
  

  25.3  

 
 

  %  

 
  Operating margin    

  21.1  

 
 

  %  

 
  

  26.3  

 
 

  %  

 
  

  -  

 
 

 

 
  

  (5.2  

 
 

  %)  

 
         
  Normalized earnings from operations    

  38,238  

 
 

 

 
  

  26,355  

 
 

 

 
  

  11,883  

 
 

 

 
  

  45.1  

 
 

  %  

 
  Normalized operating margin    

  24.5  

 
 

  %  

 
  

  26.4  

 
 

  %  

 
  

  -  

 
 

 

 
  

  (1.9  

 
 

  %)  

 
         
  Adjusted EBITDA    

  43,832  

 
 

 

 
  

  30,468  

 
 

 

 
  

  13,364  

 
 

 

 
  

  43.9  

 
 

  %  

 
  Adjusted EBITDA margin    

  28.1  

 
 

  %  

 
  

  30.5  

 
 

  %  

 
  

  -  

 
 

 

 
  

  (2.4  

 
 

  %)  

 
         
         
 

  Strategic Partners  

 
        
   

  Three months ended  

 

  December 31  

 
    
   

  2022  

 
 

 

 
  

  2021  

 
 

 

 
  

  $ Change  

 
  

  % Change  

 
         
Revenue   

36,779

 
 

 

 
  

30,054

 
 

 

 
  

6,725

 
 

 

 
  

22.4

 
 

%

 
         
Gross profit   

5,844

 
 

 

 
  

4,259

 
 

 

 
  

1,585

 
 

 

 
  

37.2

 
 

%

 
Gross profit margin   

15.9

 
 

%

 
  

14.2

 
 

%

 
  

-

 
 

 

 
  

1.7

 
 

%

 
         
Selling, general and administrative expenses   

1,603

 
 

 

 
  

1,616

 
 

 

 
  

(13

 
 

)

 
  

(0.8

 
 

%)

 
Normalized selling, general and administrative expenses   

1,603

 
 

 

 
  

1,567

 
 

 

 
  

36

 
 

 

 
  

2.3

 
 

%

 
         
  Earnings from operations    

  4,241  

 
 

 

 
  

  2,643  

 
 

 

 
  

  1,598  

 
 

 

 
  

  60.5  

 
 

  %  

 
  Operating margin    

  11.5  

 
 

  %  

 
  

  8.8  

 
 

  %  

 
  

  -  

 
 

 

 
  

  2.7  

 
 

  %  

 
         
  Normalized earnings from operations    

  4,241  

 
 

 

 
  

  2,692  

 
 

 

 
  

  1,549  

 
 

 

 
  

  57.5  

 
 

  %  

 
  Normalized operating margin    

  11.5  

 
 

  %  

 
  

  9.0  

 
 

  %  

 
  

  -  

 
 

 

 
  

  2.6  

 
 

  %  

 
         
  Adjusted EBITDA    

  5,039  

 
 

 

 
  

  3,303  

 
 

 

 
  

  1,736  

 
 

 

 
  

  52.6  

 
 

  %  

 
  Adjusted EBITDA margin    

  13.7  

 
 

  %  

 
  

  11.0  

 
 

  %  

 
  

  -  

 
 

 

 
  

  2.7  

 
 

  %  

 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Jamieson Brands          
   

  Twelve months ended  

 

  December 31  

 
    
   

  2022  

 
 

 

 
  

  2021  

 
 

 

 
  

  $ Change  

 
  

  % Change  

 
         
Revenue   

439,147

 
 

 

 
  

343,245

 
 

 

 
  

95,902

 
 

 

 
  

27.9

 
 

%

 
         
Gross profit   

184,039

 
 

 

 
  

148,371

 
 

 

 
  

35,668

 
 

 

 
  

24.0

 
 

%

 
Gross profit margin   

41.9

 
 

%

 
  

43.2

 
 

%

 
  

-

 
 

 

 
  

(1.3

 
 

%)

 
         
Normalized gross profit   

184,832

 
 

 

 
  

149,024

 
 

 

 
  

35,808

 
 

 

 
  

24.0

 
 

%

 
Normalized gross profit margin   

42.1

 
 

%

 
  

43.4

 
 

%

 
  

-

 
 

 

 
  

(1.3

 
 

%)

 
         
Selling, general and administrative expenses   

103,996

 
 

 

 
  

74,056

 
 

 

 
  

29,940

 
 

 

 
  

40.4

 
 

%

 
Normalized selling, general and administrative expenses   

86,423

 
 

 

 
  

70,854

 
 

 

 
  

15,569

 
 

 

 
  

22.0

 
 

%

 
         
Share-based compensation   

4,910

 
 

 

 
  

5,672

 
 

 

 
  

(762

 
 

)

 
  

(13.4

 
 

%)

 
         
  Earnings from operations    

  75,133  

 
 

 

 
  

  68,643  

 
 

 

 
  

  6,490  

 
 

 

 
  

  9.5  

 
 

  %  

 
  Operating margin    

  17.1  

 
 

  %  

 
  

  20.0  

 
 

  %  

 
  

  -  

 
 

 

 
  

  (2.9  

 
 

  %)  

 
         
  Normalized earnings from operations    

  93,499  

 
 

 

 
  

  73,412  

 
 

 

 
  

  20,087  

 
 

 

 
  

  27.4  

 
 

  %  

 
  Normalized operating margin    

  21.3  

 
 

  %  

 
  

  21.4  

 
 

  %  

 
  

  -  

 
 

 

 
  

  (0.1  

 
 

  %)  

 
         
  Adjusted EBITDA    

  113,088  

 
 

 

 
  

  90,301  

 
 

 

 
  

  22,787  

 
 

 

 
  

  25.2  

 
 

  %  

 
  Adjusted EBITDA margin    

  25.8  

 
 

  %  

 
  

  26.3  

 
 

  %  

 
  

  -  

 
 

 

 
  

  (0.5  

 
 

  %)  

 
         
         
  Strategic Partners          
   

  Twelve months ended  

 

  December 31  

 
    
   

  2022  

 
 

 

 
  

  2021  

 
 

 

 
  

  $ Change  

 
  

  % Change  

 
         
Revenue   

108,222

 
 

 

 
  

107,787

 
 

 

 
  

435

 
 

 

 
  

0.4

 
 

%

 
         
Gross profit   

14,299

 
 

 

 
  

14,070

 
 

 

 
  

229

 
 

 

 
  

1.6

 
 

%

 
Gross profit margin   

13.2

 
 

%

 
  

13.1

 
 

%

 
  

-

 
 

 

 
  

0.1

 
 

%

 
         
Selling, general and administrative expenses   

6,243

 
 

 

 
  

6,683

 
 

 

 
  

(440

 
 

)

 
  

(6.6

 
 

%)

 
Normalized selling, general and administrative expenses   

6,195

 
 

 

 
  

6,417

 
 

 

 
  

(222

 
 

)

 
  

(3.5

 
 

%)

 
         
  Earnings from operations    

  8,056  

 
 

 

 
  

  7,387  

 
 

 

 
  

  669  

 
 

 

 
  

  9.1  

 
 

  %  

 
  Operating margin    

  7.4  

 
 

  %  

 
  

  6.9  

 
 

  %  

 
  

  -  

 
 

 

 
  

  0.5  

 
 

  %  

 
         
  Normalized earnings from operations    

  8,104  

 
 

 

 
  

  7,653  

 
 

 

 
  

  451  

 
 

 

 
  

  5.9  

 
 

  %  

 
  Normalized operating margin    

  7.5  

 
 

  %  

 
  

  7.1  

 
 

  %  

 
  

  -  

 
 

 

 
  

  0.4  

 
 

  %  

 
         
  Adjusted EBITDA    

  10,673  

 
 

 

 
  

  9,795  

 
 

 

 
  

  878  

 
 

 

 
  

  9.0  

 
 

  %  

 
  Adjusted EBITDA margin    

  9.9  

 
 

  %  

 
  

  9.1  

 
 

  %  

 
  

  -  

 
 

 

 
  

  0.8  

 
 

  %  

 
 

  Non-IFRS and Other Financial Measures  

 

This press release makes reference to certain financial measures, including non-IFRS financial measures that are historical, non-IFRS measures that are forward-looking, non-GAAP ratios and supplementary financial measures. Management uses these financial measures for purposes of comparison to prior periods and development of future projections and earnings growth prospects. This information is also used by management to measure the profitability of ongoing operations and in analyzing the Company's business performance and trends. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company's results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of the Company's financial information reported under IFRS. The Company uses the following non-IFRS financial measures: "EBITDA", "Adjusted EBITDA" and "Adjusted net earnings", the most directly comparable financial measure for each that is disclosed in its financial statements being net earnings, "normalized gross profit", "normalized SG&A", "normalized earnings from operations", "cash from operating activities before working capital considerations" and "net debt", the most directly comparable financial measures for each that is disclosed in its financial statements being gross profit, SG&A, earnings from operations, cash flows from operating activities, and long-term debt, respectively, the following non-IFRS ratios: "Adjusted EBITDA margin", "Adjusted diluted earnings per share", "normalized gross profit margin", "normalized operating margin", and the following supplementary financial measures: "gross profit margin" and "operating margin" to provide supplemental measures of the Company's operating performance and thus highlight trends in the Company's core business that may not otherwise be apparent when relying solely on IFRS financial measures. Management also uses non-IFRS and supplementary financial measures in order to prepare annual operating budgets and to determine components of management compensation. For an explanation of the composition of each such measure and the usefulness and additional uses of each by management, see the " How we Assess the Performance of our Business " section of the MD&A, which is incorporated by reference. See below for a quantitative reconciliation of each non-IFRS financial measure to its most directly comparable financial measure disclosed in the Company's financial statements to which the measure relates.

 

The following tables provide a quantitative reconciliation of net earnings to EBITDA, Adjusted EBITDA, and Adjusted net earnings, as well as gross profit to normalized gross profit, SG&A to normalized SG&A, earnings from operations to normalized earnings from operations, each of which are non-IFRS financial measures (see the " Non-IFRS and Other Financial Measures " of this press release for further information on each non-IFRS financial measure) for the three and twelve months ended December 31, 2022 and December 31, 2021.

 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
 

  Reconciliation of Non-IFRS Financial Measures  

 

In thousands of Canadian dollars

 
     
    Three months ended     Twelve months ended  
    December 31     December 31  
   

  2022  

 
 

 

 
  

  2021  

 
 

 

 
  

  2022  

 
 

 

 
  

  2021  

 
 

 

 
         
  Net earnings    

  22,091  

 
 

 

 
  

  20,190  

 
 

 

 
  

  52,808  

 
 

 

 
  

  52,082  

 
 

 

 
  Add:          
Provision for income taxes   

8,278

 
 

 

 
  

6,966

 
 

 

 
  

17,695

 
 

 

 
  

18,383

 
 

 

 
Interest expense and other financing costs   

5,757

 
 

 

 
  

1,366

 
 

 

 
  

12,417

 
 

 

 
  

5,657

 
 

 

 
Depreciation of property, plant, and equipment   

3,579

 
 

 

 
  

2,629

 
 

 

 
  

12,153

 
 

 

 
  

10,006

 
 

 

 
Amortization of intangible assets   

1,496

 
 

 

 
  

1,074

 
 

 

 
  

5,095

 
 

 

 
  

4,268

 
 

 

 
         
  Earnings before interest, taxes, depreciation, and amortization (EBITDA)    

  41,201  

 
 

 

 
  

  32,225  

 
 

 

 
  

  100,168  

 
 

 

 
  

  90,396  

 
 

 

 
  Add EBITDA adjustments:          
Share-based compensation (1)   

1,317

 
 

 

 
  

1,021

 
 

 

 
  

4,910

 
 

 

 
  

5,672

 
 

 

 
Foreign exchange loss (gain)   

978

 
 

 

 
  

352

 
 

 

 
  

269

 
 

 

 
  

(92

 
 

)

 
Acquisition related cost (2)   

3,165

 
 

 

 
  

-

 
 

 

 
  

12,919

 
 

 

 
  

-

 
 

 

 
IT system implementation (3)   

1,417

 
 

 

 
  

-

 
 

 

 
  

4,527

 
 

 

 
  

-

 
 

 

 
COVID-19 related costs (4)   

-

 
 

 

 
  

72

 
 

 

 
  

175

 
 

 

 
  

2,409

 
 

 

 
Business integration (5)   

-

 
 

 

 
  

-

 
 

 

 
  

-

 
 

 

 
  

1,852

 
 

 

 
Amortization of fair value adjustments (6)   

793

 
 

 

 
  

-

 
 

 

 
  

793

 
 

 

 
  

-

 
 

 

 
Other   

-

 
 

 

 
  

101

 
 

 

 
  

-

 
 

 

 
  

(141

 
 

)

 
  Adjusted EBITDA    

  48,871  

 
 

 

 
  

  33,771  

 
 

 

 
  

  123,761  

 
 

 

 
  

  100,096  

 
 

 

 
Provision for income taxes   

(8,278

 
 

)

 
  

(6,966

 
 

)

 
  

(17,695

 
 

)

 
  

(18,383

 
 

)

 
Interest expense and other financing costs   

(5,757

 
 

)

 
  

(1,366

 
 

)

 
  

(12,417

 
 

)

 
  

(5,657

 
 

)

 
Depreciation of property, plant, and equipment   

(3,579

 
 

)

 
  

(2,629

 
 

)

 
  

(12,153

 
 

)

 
  

(10,006

 
 

)

 
Amortization of intangible assets   

(1,496

 
 

)

 
  

(1,074

 
 

)

 
  

(5,095

 
 

)

 
  

(4,268

 
 

)

 
Share-based compensation (7)   

(1,317

 
 

)

 
  

(1,108

 
 

)

 
  

(6,309

 
 

)

 
  

(5,497

 
 

)

 
Tax effect of normalization adjustments   

(1,685

 
 

)

 
  

(139

 
 

)

 
  

(4,943

 
 

)

 
  

(1,068

 
 

)

 
  Adjusted net earnings    

  26,759  

 
 

 

 
  

  20,489  

 
 

 

 
  

  65,149  

 
 

 

 
  

  55,217  

 
 

 

 
         
         
    Three months ended     Twelve months ended  
    December 31     December 31  
   

  2022  

 
 

 

 
  

  2021  

 
 

 

 
  

  2022  

 
 

 

 
  

  2021  

 
 

 

 
         
  Gross profit    

  71,189  

 
 

 

 
  

  49,416  

 
 

 

 
  

  198,338  

 
 

 

 
  

  162,441  

 
 

 

 
Business integration (5)   

-

 
 

 

 
  

-

 
 

 

 
  

-

 
 

 

 
  

653

 
 

 

 
Amortization of fair value adjustments (6)   

793

 
 

 

 
  

-

 
 

 

 
  

793

 
 

 

 
  

-

 
 

 

 
  Normalized gross profit    

  71,982  

 
 

 

 
  

  49,416  

 
 

 

 
  

  199,131  

 
 

 

 
  

  163,094  

 
 

 

 
  Normalized gross profit margin    

  37.3  

 
 

  %  

 
  

  38.1  

 
 

  %  

 
  

  36.4  

 
 

  %  

 
  

  36.2  

 
 

  %  

 
         
  Selling, general and administrative expenses    

  32,768  

 
 

 

 
  

  19,521  

 
 

 

 
  

  110,239  

 
 

 

 
  

  80,739  

 
 

 

 
Acquisition related cost (2)   

(3,165

 
 

)

 
  

-

 
 

 

 
  

(12,919

 
 

)

 
  

-

 
 

 

 
IT system implementation (3)   

(1,417

 
 

)

 
  

-

 
 

 

 
  

(4,527

 
 

)

 
  

-

 
 

 

 
COVID-19 related costs (4)   

-

 
 

 

 
  

(72

 
 

)

 
  

(175

 
 

)

 
  

(2,409

 
 

)

 
Business integration (5)   

-

 
 

 

 
  

-

 
 

 

 
  

-

 
 

 

 
  

(1,200

 
 

)

 
Other   

-

 
 

 

 
  

(101

 
 

)

 
  

-

 
 

 

 
  

141

 
 

 

 
  Normalized selling, general and administrative expenses    

  28,186  

 
 

 

 
  

  19,348  

 
 

 

 
  

  92,618  

 
 

 

 
  

  77,271  

 
 

 

 
         
  Earnings from operations    

  37,104  

 
 

 

 
  

  28,874  

 
 

 

 
  

  83,189  

 
 

 

 
  

  76,030  

 
 

 

 
Acquisition related cost (2)   

3,165

 
 

 

 
  

-

 
 

 

 
  

12,919

 
 

 

 
  

-

 
 

 

 
IT system implementation (3)   

1,417

 
 

 

 
  

-

 
 

 

 
  

4,527

 
 

 

 
  

-

 
 

 

 
COVID-19 related costs (4)   

-

 
 

 

 
  

72

 
 

 

 
  

175

 
 

 

 
  

2,409

 
 

 

 
Business integration (5)   

-

 
 

 

 
  

-

 
 

 

 
  

-

 
 

 

 
  

1,853

 
 

 

 
Amortization of fair value adjustments (6)   

793

 
 

 

 
  

-

 
 

 

 
  

793

 
 

 

 
  

-

 
 

 

 
Share based compensation   

-

 
 

 

 
  

-

 
 

 

 
  

-

 
 

 

 
  

914

 
 

 

 
Other   

-

 
 

 

 
  

101

 
 

 

 
  

-

 
 

 

 
  

(141

 
 

)

 
  Normalized earnings from operations    

  42,479  

 
 

 

 
  

  29,047  

 
 

 

 
  

  101,603  

 
 

 

 
  

  81,065  

 
 

 

 
  Normalized operating margin    

  22.0  

 
 

  %  

 
  

  22.4  

 
 

  %  

 
  

  18.6  

 
 

  %  

 
  

  18.0  

 
 

  %  

 
 
                     
 

(1)

 
 

 

 
 

Pertains to the expenses relating to our equity based long-term incentive plan (the "LTIP"), along with associated payroll taxes.

 
 

(2)

 
 

 

 
 

Expenses relating to the youtheory acquisition and integration.

 
 

(3)

 
 

 

 
 

Relates to system implementation costs to advance our supply chain planning infrastructure. Unlike other system improvement projects with costs capitalized, due to its cloud-based nature, these system implementation costs are expensed accordingly.

 
 

(4)

 
 

 

 
 

Costs related to COVID-19 which do not reflect the ongoing costs of operation.

 
 

(5)

 
 

 

 
 

Prior year expenses mainly pertained to start-up costs to complete our transition to a third-party logistics provider to make room for capacity expansion at our existing operations.

 
 

(6)

 
 

 

 
 

Represents the post-closing amortization of the fair value increase of acquired inventories related to the youtheory acquisition.

 
 

(7)

 
 

 

 
 

Costs pertaining to our LTIP and tax benefits realized on the vesting of certain share-based awards. Prior year expenses included the acceleration of share-based compensation expense in relation to our CEO transition.

 
 

 

 

  

  

  Investor and Media Contact Information:
Jamieson Wellness
Ruth Winker
416-705-5437
rwinker@jamiesonlabs.com  

 

News Provided by Business Wire via QuoteMedia

JWEL:CA
The Conversation (0)
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Invion Limited

Invion Limited

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial

Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients
with acute myocarditis, with topline data expected in Q2 2025

Keep reading...Show less

Latest Press Releases

Related News

×